Heparin Sodium Wockhardt Uk (Heparin Sodium)

Heparin Sodium Wockhardt UK is indicated for several antithrombotic indications in hospital settings.

• Prevention and treatment of venous thromboembolism, including deep vein thrombosis and pulmonary embolism.
• Prophylaxis of deep vein thrombosis in patients undergoing surgery or immobilization.
• Management of acute coronary syndromes, such as unstable angina and non‑ST‑segment elevation myocardial infarction.
• Use during cardiac bypass or other cardiovascular procedures requiring anticoagulation.
• Treatment of clotting disorders in patients at risk for heparin‑induced thrombocytopenia, under specialist guidance.

Adverse reactions to Heparin Sodium Wockhardt UK vary in frequency and severity.

Common

• Minor bleeding at the injection site.
• Small bruising or hematoma formation.
• Mild nausea or vomiting.
• Transient elevation of liver enzymes.
• Mild thrombocytopenia without clinical bleeding.
• Elevated activated partial thromboplastin time (aPTT).

Serious

• Major hemorrhage, including intracranial or gastrointestinal bleeding.
• Heparin‑induced thrombocytopenia (HIT) with risk of thrombosis.
• Spinal or epidural hematoma when used near the central nervous system.
• Allergic reactions such as urticaria, angioedema, or anaphylaxis.
• Severe drop in blood pressure (hypotension) due to systemic anticoagulation.
• Organ failure secondary to massive bleeding.

When prescribing Heparin Sodium Wockhardt UK, clinicians should consider several safety precautions to minimize risk.

• Assess baseline coagulation status and platelet count before initiation.
• Adjust dose in patients with renal or hepatic impairment.
• Monitor activated partial thromboplastin time (aPTT) regularly during therapy.
• Avoid use in patients with active major bleeding or recent intracranial hemorrhage.
• Use caution in pregnancy; benefits must outweigh potential risks.
• Discontinue promptly if signs of heparin‑induced thrombocytopenia appear.
• Review concomitant use of other anticoagulants or antiplatelet agents.

Heparin Sodium Wockhardt UK can interact with other medications that affect hemostasis or platelet function.

Avoid

• Concurrent use of other parenteral anticoagulants (e.g., direct thrombin inhibitors) unless specifically directed.
• Combination with thrombolytic agents such as alteplase or streptokinase.
• Use with high‑dose aspirin or non‑steroidal anti‑inflammatory drugs (NSAIDs) that increase bleeding risk.

Use with caution

• Dual antiplatelet therapy (e.g., clopidogrel plus aspirin).
• Certain antibiotics (e.g., cefazolin) that may potentiate anticoagulant effect.
• Glycoprotein IIb/IIIa inhibitors.
• Vitamin K antagonists (warfarin) during transition phases.
• Antifibrinolytics (e.g., tranexamic acid) when bleeding control is needed.